

[ Fri, Oct 04th 2024
] - WOPRAI

[ Tue, Oct 01st 2024
] - WOPRAI

[ Mon, Sep 30th 2024
] - WOPRAI

[ Tue, Sep 24th 2024
] - WOPRAI
[ Tue, Sep 24th 2024
] - WOPRAI

[ Tue, Sep 17th 2024
] - WOPRAI

[ Mon, Sep 09th 2024
] - WOPRAI

[ Fri, Aug 30th 2024
] - WOPRAI

[ Mon, Aug 19th 2024
] - WOPRAI

[ Thu, Aug 15th 2024
] - WOPRAI

[ Tue, Aug 13th 2024
] - WOPRAI

[ Wed, Aug 07th 2024
] - WOPRAI

[ Mon, Jul 29th 2024
] - WOPRAI

[ Mon, Jul 22nd 2024
] - WOPRAI

[ Wed, Jul 17th 2024
] - WOPRAI

[ Wed, Feb 28th 2024
] - WOPRAI


[ Fri, Jan 06th 2023
] - WOPRAI







[ Thu, Aug 17th 2017
] - WOPRAI


Jason Kolbert Maintained (TRVI) at Strong Buy and Held Target at $21 on, Oct 4th, 2024
Jason Kolbert of EF Hutton, Maintained "Trevi Therapeutics, Inc." (TRVI) at Strong Buy and Held Target at $21 on, Oct 4th, 2024.
Jason has made no other calls on TRVI in the last 4 months.
There are 4 other peers that have a rating on TRVI. Out of the 4 peers that are also analyzing TRVI, 0 agree with Jason's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Jason
- Faisal Khurshid of "Leerink Partners" Initiated at Buy and Held Target at $7 on, Monday, September 9th, 2024
- Oren Livnat of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $6 on, Friday, August 30th, 2024
- Ryan Deschner of "Raymond James" Initiated at Buy and Held Target at $9 on, Friday, August 30th, 2024
- Brandon Folkes of "Rodman & Renshaw" Initiated at Strong Buy and Held Target at $7 on, Thursday, June 13th, 2024